Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21842289 | 1.00 | NAAA (0.50) | NAAAKEAP1NFE2L2CHRM1EPHX2 | |
| SCHEMBL23975140 | 1.00 | NAAA (0.50) | NAAAKEAP1NFE2L2CHRM1EPHX2 | |
| SCHEMBL23975361 | 0.94 | SMN1; SMN2 (0.44) | NAAAKEAP1NFE2L2CHRM1EPHX2 | |
| SCHEMBL21842360 | 0.94 | SMN1; SMN2 (0.44) | NAAAKEAP1NFE2L2CHRM1EPHX2 | |
| SCHEMBL23975365 | 0.94 | SMN1; SMN2 (0.44) | NAAAKEAP1NFE2L2CHRM1EPHX2 | |
| SCHEMBL23975357 | 0.86 | SMN1; SMN2 (0.50) | NAAAKEAP1NFE2L2CHRM1EPHX2 | |
| SCHEMBL23975143 | 0.84 | SMN1; SMN2 (0.48) | NAAAKEAP1NFE2L2CHRM1EPHX2 | |
| SCHEMBL26158778 | 0.81 | SMN1; SMN2 (0.48) | NAAAKEAP1NFE2L2CHRM1EPHX2 | |
| SCHEMBL23975372 | 0.81 | NAAA (0.68) | NAAAKEAP1NFE2L2EPHX2NAMPT | |
| SCHEMBL23975246 | 0.81 | NAAA (0.68) | NAAAKEAP1NFE2L2EPHX2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | HAVCR2, CUL4A, PSMC3 | NAAA 914/4885KEAP1 194/4885NFE2L2 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.